Skip to main content
. 2016 Sep 1;7(40):66032–66050. doi: 10.18632/oncotarget.11797

Figure 11. Rig-G inhibits NF-κB activation through downregulation of MiR21/PTEN/Akt and miR181b-1/CYLD pathways.

Figure 11

A. The cells were respectively cultured in the presence or absence of Dox (2 μg/mL) for 24 h. Real-time PCR analysis of MicroRNA expression levels in A549 cell lines with and without Rig-G overexpression. The results are expressed as the mean ± SEM (n = 5), ***p < 0.001. B. NF-κB activation assay of A549 sublines pTRE and Tet-On Rig-G treated with miR-21 (100 nM), miR-181b-1 (100 nM) for 24 h. The results are expressed as the mean ± SEM (n = 3), ***p < 0.001. C. A549 sublines pTRE and Tet-On Rig-G were analyzed for the expression of the indicated proteins by immunoblot analysis. D. NF-κB activation assay of A549 sublines pTRE and Tet-On Rig-G treated with PTEN inhibitor bpV (phen) (10 μM) for 24 h. The results are expressed as the mean ± SEM (n = 3), ***p < 0.001. E. Real-time PCR analysis of CYLD mRNA expression in A549 sublines pTRE and Tet-On Rig-G. The cells were respectively cultured in the presence or absence of Dox (2 μg/mL). The results are expressed as the mean ± SEM (n = 5), ***p < 0.001. F. NF-κB activity (ELISA assay) in A549 sublines pTRE and Tet-On Rig-G treated with siCYLD or siNC (negative control). The results are expressed as the mean ± SEM (n = 3), ***p < 0.001.